Novel Drug Delivers Long-Term Cholesterol Reduction

ACC Conference Reporter

ACC.17 | WASHINGTON, DC — A novel drug that dramatically lowers LDL cholesterol and needs to be administered only a few times a year has reached a new milestone. Positive results from a phase II study with the drug, now known as inclisiran, were reported at the American College of Cardiology meeting here and published simultaneously in the New England Journal of Medicine. Read More >>>

Keywords: ACC17, ACC Annual Scientific Session


< Back to Listings